Recurrent Arthritis and Anti-cyclic Citrullinated Peptide Positivity during Interferon-beta 1a Treatment in Two Patients with Multiple Sclerosis
,
Abstract
Interferon (IFN) beta is the most widely prescribed disease-modifying drug for multiple sclerosis (MS). However, some adverse reactions are observed in course of IFN-beta therapy. This article presents two cases of female patients diagnosed with relapsing-remitting MS who developed inflammatory musculoskeletal manifestations, following IFN-beta 1a therapy. In the first patient recurrent arthritis developed a week after initiation of IFN-beta, which improved few weeks after a switch to glatiramer acetate. The second patient developed recurrent arthritis 1 month after IFN-beta 1a therapy who suffered painful arthritis despite discontinuation of the medication. Both patients were seropositive for anti- cyclic citrullinated peptide; the first patient was a positive rheumatoid factor (RF) and the second patient was both positive RF and anti-Ro. The role of IFN-beta in the setting of inflammatory musculoskeletal disease remains unclear. To minimize its side effects, review of these antibodies may be required in patients who are candidates for this therapy.
Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, et al. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study. Mult Scler 2014; 20(9): 1265-8.
Rot U, Ledinek AH. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.Clin Neurol Neurosurg 2013; 115(Suppl 1):S79-S81.
Cruz BA, Queiroz ED, Nunes SV, Cruz FA, Campos GB, Monteiro EL, et al. Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report. Arq Neuropsiquiatr 2000; 58(2B):556-9.
Altintas A, Alici Y, Melikoglu M, Siva A.Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002; 8(6): 534-6.
Strueby L, Nair B, Kirk A, Taylor-Gjevre RM.Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta. Scand J Rheumatol 2005; 34(6): 485-8.
Bahri DM, Khiari H, Essouri A, Laadhar L, Zaraa I, Mrabet A, et al. Systemic lupus erythematosus induced by interferon beta1 therapy in a patient with multiple sclerosis. Fundam Clin Pharmacol 2012; 26(2): 210-1.
Conti V, Esposito A, Cagliuso M, Fantauzzi A, Pastori D, Mezzaroma I, et al. Undifferentiated connective tissue disease-an unsolved problem: revision of literature and case studies. Int J Immunopathol Pharmacol 2010; 23(1): 271-8.
Hanson KA, Agashivala N, Wyrwich KW, Raimundo K, Kim E, Brandes DW. Treatment selection and experience in multiple sclerosis: Survey of neurologists. Patient Prefer Adherence 2014; 8: 415-22.
Toussirot E, Bereau M, Bossert M, Malkoun I, Lohse A. Occurrence of psoriatic arthritis during interferon beta 1a treatment for multiple sclerosis. Case Rep Rheumatol 2014; 2014:949317.
De Santi L, Costantini MC, Annunziata P.Long time interval between multiple sclerosis onset and occurrence of primary Sjogren's syndrome in a woman treated with interferon-beta. Acta Neurol cand 2005; 112(3): 194-6.
Levesque MC, Ward FE, Jeffery DR, Weinberg JB. Interferon-beta1A-induced polyarthritis in a patient with the HLA- DRB1*0404 allele. Arthritis Rheum 1999;42(3): 569-73.
Russo R, Tenembaum S, Moreno MJ, Battagliotti C. Interferon-beta1a-induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: comment on the case report by Levesque et al. ArthritisRheum 2000; 43(5): 1190.
Alsalameh S, Manger B, Kern P, Kalden J.New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 1998; 41(4): 754.
Sladkova V, Mares J, Lubenova B, Hlustik P, Kanovsky P. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy.Neuro Endocrinol Lett 2011; 32(1): 4-6.
Buchanan S, Rosemergy I, Healy P. Drug- induced subacute cutaneous lupus erythematosus due to treatment with interferon beta-1a. N Z Med J 2013; 126(1379): 98-101.
Chakravarty SD, Harris ME, Schreiner AM, Crow MK. Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review. Semin Arthritis Rheum 2012; 42(2): 206-12.
Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases.Arthritis Res Ther 2010; 12(Suppl 1): S5.
Axtell RC, Raman C, Steinman L. Interferon- beta exacerbates Th17-mediated inflammatory disease. Trends Immunol 2011; 32(6): 272-7.
van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, et al. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen- induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004; 6(3): R239-R249.
Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009; 10(4): 285-96.
| Files | ||
| Issue | Vol 1 No 2 (2016): Spring | |
| Section | Case Report(s) | |
| Keywords | ||
| Arthritis Multiple sclerosis Interferon-beta | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
